7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Multiplex secretome engineering enhances recombinant protein production and purity

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Host cell proteins (HCPs) are process-related impurities generated during biotherapeutic protein production. HCPs can be problematic if they pose a significant metabolic demand, degrade product quality, or contaminate the final product. Here, we present an effort to create a “clean” Chinese hamster ovary (CHO) cell by disrupting multiple genes to eliminate HCPs. Using a model of CHO cell protein secretion, we predict that the elimination of unnecessary HCPs could have a non-negligible impact on protein production. We analyze the HCP content of 6-protein, 11-protein, and 14-protein knockout clones. These cell lines exhibit a substantial reduction in total HCP content (40%-70%). We also observe higher productivity and improved growth characteristics in specific clones. The reduced HCP content facilitates purification of a monoclonal antibody. Thus, substantial improvements can be made in protein titer and purity through large-scale HCP deletion, providing an avenue to increased quality and affordability of high-value biopharmaceuticals.

          Abstract

          Host cell proteins can contaminate biotherapeutics and compromise and degrade their quality. Here the authors use modelling and CRISPR to delete secreted host proteins in CHO cells, leading to improved monoclonal antibody production and purity.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.

          To generate industrially applicable new host cell lines for antibody production with optimizing antibody-dependent cellular cytotoxicity (ADCC) we disrupted both FUT8 alleles in a Chinese hamster ovary (CHO)/DG44 cell line by sequential homologous recombination. FUT8 encodes an alpha-1,6-fucosyltransferase that catalyzes the transfer of fucose from GDP-fucose to N-acetylglucosamine (GlcNAc) in an alpha-1,6 linkage. FUT8(-/-) cell lines have morphology and growth kinetics similar to those of the parent, and produce completely defucosylated recombinant antibodies. FUT8(-/-)-produced chimeric anti-CD20 IgG1 shows the same level of antigen-binding activity and complement-dependent cytotoxicity (CDC) as the FUT8(+/+)-produced, comparable antibody, Rituxan. In contrast, FUT8(-/-)-produced anti-CD20 IgG1 strongly binds to human Fcgamma-receptor IIIa (FcgammaRIIIa) and dramatically enhances ADCC to approximately 100-fold that of Rituxan. Our results demonstrate that FUT8(-/-) cells are ideal host cell lines to stably produce completely defucosylated high-ADCC antibodies with fixed quality and efficacy for therapeutic use.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Recent advances in large-scale production of monoclonal antibodies and related proteins.

            The rapid development of high-yielding and robust manufacturing processes for monoclonal antibodies is an area of significant focus in the biopharmaceutical landscape. Advances in mammalian cell culture have taken titers to beyond the 5 g/l mark. Platform approaches to downstream process development have become widely established. Continuous evolution of these platforms is occurring as experience with a wider range of products is accrued. The increased cell culture productivity has shifted the attention of bioprocess development to operations downstream of the production bioreactor. This has rejuvenated interest in the use of non-chromatographic separation processes. Here, we review the current state-of-the-art industrial production processes, focusing on downstream technologies, for antibodies and antibody-related products and discuss future avenues for evolution. Copyright 2010 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Recovery and purification process development for monoclonal antibody production

                Bookmark

                Author and article information

                Contributors
                stef.kol@gmail.com
                nlewisres@ucsd.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                20 April 2020
                20 April 2020
                2020
                : 11
                : 1908
                Affiliations
                [1 ]ISNI 0000 0001 2181 8870, GRID grid.5170.3, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Building 220, Kemitorvet, ; 2800 Kgs. Lyngby, Denmark
                [2 ]ISNI 0000 0001 2107 4242, GRID grid.266100.3, The Novo Nordisk Foundation Center for Biosustainability at the University of California, San Diego, School of Medicine, ; La Jolla, CA 92093 USA
                [3 ]Department of Bioengineering, University of California, San Diego, School of Medicine, La Jolla, CA 92093 USA
                [4 ]Department of Pediatrics, University of California, San Diego, School of Medicine, La Jolla, CA 92093 USA
                [5 ]ISNI 0000 0001 2292 0500, GRID grid.37172.30, Department of Biological Sciences, KAIST, 291 Daehak-ro, Yuseong-gu, ; Daejeon, 305-701 Republic of Korea
                Author information
                http://orcid.org/0000-0002-1992-8242
                http://orcid.org/0000-0003-2664-8561
                http://orcid.org/0000-0002-6007-4787
                Article
                15866
                10.1038/s41467-020-15866-w
                7170862
                32313013
                0561ab66-7183-4856-a6a1-79b4d2a2dfbe
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 22 May 2019
                : 31 March 2020
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100009708, Novo Nordisk Fonden (Novo Nordisk Foundation);
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award ID: NNF10CC1016517
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100000057, U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS);
                Award ID: R35 GM119850
                Award ID: R35 GM119850
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100003141, Consejo Nacional de Ciencia y Tecnología (National Council of Science and Technology, Mexico);
                Award ID: CONACYT
                Award ID: CONACYT
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/100005909, University of California Institute for Mexico and the United States (UC MEXUS);
                Award ID: UC-MEXUS
                Award ID: UC-MEXUS
                Award Recipient :
                Funded by: U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                biologics,metabolic engineering,synthetic biology,computational models
                Uncategorized
                biologics, metabolic engineering, synthetic biology, computational models

                Comments

                Comment on this article